PA8604001A1 - Profarmaco inhibidor de beta-lactamasa - Google Patents
Profarmaco inhibidor de beta-lactamasaInfo
- Publication number
- PA8604001A1 PA8604001A1 PA20048604001A PA8604001A PA8604001A1 PA 8604001 A1 PA8604001 A1 PA 8604001A1 PA 20048604001 A PA20048604001 A PA 20048604001A PA 8604001 A PA8604001 A PA 8604001A PA 8604001 A1 PA8604001 A1 PA 8604001A1
- Authority
- PA
- Panama
- Prior art keywords
- beta
- lactama
- antibiotic
- same
- mammer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/861—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a hydrocarbon radical or a substituted hydrocarbon radical, directly attached in position 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE DAN A CONOCER PROFARMACOS DE SULFONA DEL ACIDO 6-ß-HIDROXIMETILPENICILANICO QUE TIENE LA ESTRUCTURA EN LA QUE R ES H O METILO, CADA X ES METILENO, E Y ES O, O EN LA QUE R ES H, CADA X ES O E Y ES METILENO, Y SOLVATOS DE LOS MISMOS. SE DAN A CONOCER TAMBIEN COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN PROFARMACO DE LA PRESENTE INVENCION, O UN SOLVATO DEL MISMO, UN ANTIBIOTICO BETA-LACTAMA OPCIONAL Y AL MENOS UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. SE DA A CONOCER ADEMAS UN PROCEDIMIENTO PARA AUMENTAR LA EFICACIA TERAPEUTICA DE UN ANTIBIOTICO BETA-LACTAMA EN UN MAMIFERO MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFICAZ DE UN ANTIBIOTICO BETA-LACTAMA Y UNA CANTIDAD QUE AUMENTA LA EFICACIA DE UN PROFARMACO DE LA PRESENTE INVENCION, O UN SOLVATO DEL MISMO. SE DA A CONOCER ADICIONALMENTE UN PROCEDIMIENTO PARA TRATAR UNA INFECCION BACTERIANA EN UN MAMIFERO MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UNA COMPOSICION FARMACEUTICA DE LA PRESENTE INVENCION A UN MAMIFERO NECESITADO DE ELLO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47645603P | 2003-06-05 | 2003-06-05 | |
| US49842203P | 2003-08-27 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8604001A1 true PA8604001A1 (es) | 2004-12-16 |
Family
ID=33514083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20048604001A PA8604001A1 (es) | 2003-06-05 | 2004-06-02 | Profarmaco inhibidor de beta-lactamasa |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050004093A1 (es) |
| EP (1) | EP1636240A1 (es) |
| JP (1) | JP2006526612A (es) |
| AR (1) | AR044482A1 (es) |
| BR (1) | BRPI0410936A (es) |
| CA (1) | CA2528065A1 (es) |
| CL (1) | CL2004001343A1 (es) |
| MX (1) | MXPA05012895A (es) |
| NL (1) | NL1026340C2 (es) |
| PA (1) | PA8604001A1 (es) |
| PE (1) | PE20050629A1 (es) |
| TW (1) | TW200504010A (es) |
| UY (1) | UY28340A1 (es) |
| WO (1) | WO2004108733A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20321762U1 (de) | 1988-05-11 | 2009-08-27 | H. Börger & Co. GmbH | Vorrichtung zum Fördern von pulverförmigem Material |
| PA8579701A1 (es) * | 2002-08-23 | 2005-05-24 | Pfizer Prod Inc | Profarmaco inhibidor de beta-lactamasa |
| GB201407506D0 (en) | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE34011B1 (en) * | 1969-03-13 | 1975-01-08 | Leo Pharm Prod Ltd | New penicillin esters |
| IE34019B1 (en) * | 1969-03-18 | 1975-01-08 | Leo Pharm Prod Ltd | New semi-synthetic penicillin esters |
| US3957764A (en) * | 1969-11-11 | 1976-05-18 | Lovens Kemiske Fabrik Produktionsaktieselskab | 6-aminopenicillanic acid derivatives |
| US3862181A (en) * | 1970-10-28 | 1975-01-21 | Squibb & Sons Inc | Process for preparing cephalosporins |
| US4397783A (en) * | 1979-03-05 | 1983-08-09 | Pfizer Inc. | Process for converting 6,6-disubstituted penicillanic acid derivatives to the 6-β-congeners |
| US4287181A (en) * | 1979-10-22 | 1981-09-01 | Pfizer Inc. | Derivatives of 6β-hydroxyalkylpenicillanic acids as β-lactamase inhibitors |
| US4432970A (en) * | 1979-11-23 | 1984-02-21 | Pfizer Inc. | 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors |
| GB2076812A (en) * | 1980-05-22 | 1981-12-09 | Ciba Geigy Ag | Penam-dioxide compounds, processes for their manufacture, and their use |
| AU559689B2 (en) * | 1981-09-22 | 1987-03-19 | Kureha Kagaku Kogyo K.K. | Penicillin derivative |
| US4406887A (en) * | 1981-10-13 | 1983-09-27 | Bristol-Myers Company | Method for treating resistant bacteria including anaerobes |
| US4377590A (en) * | 1982-05-10 | 1983-03-22 | Pfizer Inc. | Derivatives of ampicillin and amoxicillin with beta-lactamase inhibitors |
| US4428935A (en) * | 1982-05-24 | 1984-01-31 | Pfizer Inc. | Penicillanic acid dioxide prodrug |
| US4826833A (en) * | 1984-01-30 | 1989-05-02 | Pfizer Inc. | 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof |
| US4521533A (en) * | 1984-07-12 | 1985-06-04 | Pfizer Inc. | Salts of 6-alpha-(aminomethyl)penicillanic acid 1,1-dioxide esters and beta-lactam antibiotics |
| US4762921A (en) * | 1985-04-18 | 1988-08-09 | Pfizer Inc. | 6-(1-acyl-1-hydroxymethyl)penicillanic acid derivatives |
| US5200403A (en) * | 1987-07-10 | 1993-04-06 | Farmitalia Carlo Erba S.R.L. | Inhibition of βlactamase with 6 β-(substituted methyl)-penicillanic acid derivatives |
| JPH03206038A (ja) * | 1990-01-08 | 1991-09-09 | Yoshitomi Pharmaceut Ind Ltd | 抗菌剤 |
| GB9001405D0 (en) * | 1990-01-22 | 1990-03-21 | Leo Pharm Prod Ltd | New intermediates,their production and use |
| EP0544906B1 (en) * | 1990-08-20 | 1999-11-10 | Suntory Limited | Antibacterial penem esters derivatives |
| GB9208492D0 (en) * | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
| WO1999033838A1 (en) * | 1997-12-29 | 1999-07-08 | Research Corporation Technologies, Inc. | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS |
| ATE288438T1 (de) * | 1999-03-03 | 2005-02-15 | Astur Pharma Sa | Verfahren zur herstellung von dioxopenicillansäurederivaten |
| PA8579701A1 (es) * | 2002-08-23 | 2005-05-24 | Pfizer Prod Inc | Profarmaco inhibidor de beta-lactamasa |
-
2004
- 2004-05-24 BR BRPI0410936-8A patent/BRPI0410936A/pt not_active IP Right Cessation
- 2004-05-24 JP JP2006508430A patent/JP2006526612A/ja active Pending
- 2004-05-24 MX MXPA05012895A patent/MXPA05012895A/es not_active Application Discontinuation
- 2004-05-24 EP EP04734576A patent/EP1636240A1/en not_active Withdrawn
- 2004-05-24 CA CA002528065A patent/CA2528065A1/en not_active Abandoned
- 2004-05-24 WO PCT/IB2004/001824 patent/WO2004108733A1/en not_active Application Discontinuation
- 2004-06-01 CL CL200401343A patent/CL2004001343A1/es unknown
- 2004-06-02 PE PE2004000557A patent/PE20050629A1/es not_active Application Discontinuation
- 2004-06-02 UY UY28340A patent/UY28340A1/es not_active Application Discontinuation
- 2004-06-02 PA PA20048604001A patent/PA8604001A1/es unknown
- 2004-06-03 AR ARP040101928A patent/AR044482A1/es unknown
- 2004-06-04 TW TW093116149A patent/TW200504010A/zh unknown
- 2004-06-04 NL NL1026340A patent/NL1026340C2/nl not_active IP Right Cessation
- 2004-06-07 US US10/862,200 patent/US20050004093A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR044482A1 (es) | 2005-09-14 |
| TW200504010A (en) | 2005-02-01 |
| EP1636240A1 (en) | 2006-03-22 |
| MXPA05012895A (es) | 2006-02-22 |
| PE20050629A1 (es) | 2005-08-25 |
| WO2004108733A1 (en) | 2004-12-16 |
| UY28340A1 (es) | 2005-01-31 |
| BRPI0410936A (pt) | 2006-06-27 |
| US20050004093A1 (en) | 2005-01-06 |
| NL1026340C2 (nl) | 2005-09-14 |
| CL2004001343A1 (es) | 2005-04-22 |
| CA2528065A1 (en) | 2004-12-16 |
| NL1026340A1 (nl) | 2004-12-07 |
| JP2006526612A (ja) | 2006-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0108395A (pt) | Derivados de pirrolopirimidinona, processos de preparação e uso | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| BRPI0407699A (pt) | Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam | |
| AR033367A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos | |
| AR032556A1 (es) | Medicamento de accion inmediata para el tratamiento de la disfuncion sexual | |
| BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
| AR035498A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos, su uso en la preparacion de medicamentos, intermediarios para su preparacion y composiciones farmaceuticas que los contienen | |
| MX2007004783A (es) | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. | |
| HRP20060007A2 (en) | Conjugated complement cascade inhibitors | |
| AR034555A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina; composicion farmaceutica, compuesto intermediario, procedimiento para preparar dichos compuestos | |
| MXPA03002022A (es) | Conjugados de inhibidor de neuraminidas multivalentes. | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
| AR031117A1 (es) | Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica | |
| BRPI0506493A (pt) | combinações terapêuticas | |
| AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| PT1272199E (pt) | Terapias de combinacao com actividade de lesao vascular | |
| UY26564A1 (es) | Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos | |
| ZA202210355B (en) | Compositions and therapeutic uses of cannabidiol | |
| AR119061A1 (es) | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE SCAP Y MÉTODOS DE USO DE LAS MISMAS | |
| BRPI0614197B8 (pt) | composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição | |
| BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| AR044660A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| BR0211936A (pt) | Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos | |
| AR117652A1 (es) | Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas |